Robeco Institutional Asset Management B.V. Buys 224,280 Shares of Boston Scientific Co. (NYSE:BSX)

Robeco Institutional Asset Management B.V. raised its stake in shares of Boston Scientific Co. (NYSE:BSX) by 13.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,922,301 shares of the medical equipment provider’s stock after acquiring an additional 224,280 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Boston Scientific were worth $171,700,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of BSX. Sumitomo Life Insurance Co. raised its stake in shares of Boston Scientific by 11.3% during the 4th quarter. Sumitomo Life Insurance Co. now owns 99,858 shares of the medical equipment provider’s stock worth $8,919,000 after purchasing an additional 10,098 shares during the period. Moody Aldrich Partners LLC raised its stake in shares of Boston Scientific by 5.1% during the 4th quarter. Moody Aldrich Partners LLC now owns 3,347 shares of the medical equipment provider’s stock worth $299,000 after purchasing an additional 163 shares during the period. BSW Wealth Partners raised its stake in shares of Boston Scientific by 3.5% during the 4th quarter. BSW Wealth Partners now owns 7,920 shares of the medical equipment provider’s stock worth $707,000 after purchasing an additional 267 shares during the period. Patriot Financial Group Insurance Agency LLC raised its stake in shares of Boston Scientific by 12.3% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 15,410 shares of the medical equipment provider’s stock worth $1,376,000 after purchasing an additional 1,692 shares during the period. Finally, Stonegate Investment Group LLC raised its stake in shares of Boston Scientific by 1.6% during the 4th quarter. Stonegate Investment Group LLC now owns 7,827 shares of the medical equipment provider’s stock worth $699,000 after purchasing an additional 126 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Up 0.1 %

Shares of NYSE BSX opened at $102.41 on Wednesday. Boston Scientific Co. has a 12 month low of $60.78 and a 12 month high of $102.93. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $150.93 billion, a price-to-earnings ratio of 84.63, a PEG ratio of 2.63 and a beta of 0.80. The business has a 50-day moving average of $92.74 and a 200-day moving average of $85.81.

Insider Transactions at Boston Scientific

In related news, Director Edward J. Ludwig sold 4,877 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total value of $446,879.51. Following the completion of the sale, the director now owns 39,398 shares in the company, valued at $3,610,038.74. The trade was a 11.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 14,010 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the sale, the executive vice president now owns 978 shares of the company’s stock, valued at $87,306.06. The trade was a 93.47 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 29,989 shares of company stock valued at $2,702,261. 0.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

BSX has been the topic of a number of recent analyst reports. Royal Bank of Canada lifted their target price on Boston Scientific from $95.00 to $98.00 and gave the stock an “outperform” rating in a research note on Thursday, October 24th. TD Cowen lifted their price objective on Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, December 12th. Needham & Company LLC reissued a “hold” rating on shares of Boston Scientific in a report on Wednesday, November 27th. Bank of America lifted their price objective on Boston Scientific from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. Finally, BTIG Research lifted their price objective on Boston Scientific from $84.00 to $93.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Three research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and an average target price of $97.26.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.